Granules India Limited — Important, 04-12-2024: Updates

The update outlines the current status of Granules India Ltd.'s Gagillapur facility, classified by the US FDA under "Official Action Initiated" (OAI). While this classification does not affect the ongoing manufacturing and distribution of existing products, it may delay the review of pending product submissions until the OAI status is resolved. The company has implemented a comprehensive remediation plan to address the six observations raised by the US FDA, including a temporary pause in manufacturing to conduct a thorough risk assessment. Over 80% of the corrective actions are completed, with expectations for full closure by March 2025. Granules is also pushing forward with growth initiatives that include new product launches and capacity additions, reinforcing that its strategy is diversified and not solely reliant on the Gagillapur site. Overall, the company's outlook remains positive, with proactive measures in place to enhance operational compliance and drive growth.